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We report on an adult with cystic ﬁbrosis (ΔF508/G551D) with severe lung disease (forced expiratory volume (FEV1) in one second 24%
predicted) who was admitted for a pulmonary exacerbation. He was managed with maximal medical therapy, but did not have signiﬁcant
improvement until after he was started on ivacaftor on hospital day 15. He subsequently had signiﬁcant improvement in lung function with
normalization of hypercarbia, oxygen saturation on room air, and increase in FEV1 to 36% predicted. Prior to use of ivacaftor he was being
assessed for a lung transplant. However, after ivacaftor therapy for 6 months, he is no longer considering this treatment modality due to his
improvement of lung function and functional status.
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Ivacaftor (KALYDECO) is a cystic fibrosis transmembrane
conductance regulator (CFTR) potentiator that is indicated for
the treatment of cystic fibrosis (CF) in patients 6 years and
older who have a G551D mutation in the CFTR gene [1]. It was
approved by the FDA on January 31, 2012 based on the results
of two clinical studies involving 213 patients, one in patients
ages 12 years and older with baseline forced expiratory volume
in 1 second (FEV1) between 40% and 90% [2] and another in
patients ages 6 years to 11 years with baseline FEV1 between
40% and 105% [3], which showed that treatment with this
agent resulted in significant and sustained improvement in lung
function. Herein we report on a case of an adult patient with
severe lung disease (FEV1 24% before starting ivacaftor) who
was awaiting assessment for a lung transplant.⁎ Corresponding author. Tel.: +1 937 208 2873(office); fax: +1 937 208 2621.
E-mail address: haralampie1909@gmail.com (H.M. Polenakovik).
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A 39 year old male with CF was admitted to the hospital for
treatment of severe pulmonary exacerbation. As an infant he
was diagnosed with CF due to meconium ileus. He had severe
lung disease and was scheduled to undergo lung transplantation
assessment the following month. His FEV1 ranged between 1.3
and 1.44 L (34%–37% predicted) in the past 24 months. Recent
CF genotype revealed that he is heterozygous ΔF508/G551D.
He was chronically infected with 5 strains of P. aeruginosa
(PA), one of which was a multidrug resistant strain. He also had
exocrine pancreatic insufficiency and was receiving insulin for
CF related diabetes mellitus for the past 12 years. Two months
prior to the current pulmonary exacerbation, he was treated as
an inpatient for 46 days for severe pulmonary exacerbation.
Following this stay, he was discharged to home on supplemental
oxygen at 2 L/min at rest and bi-level positive airway pressure
(BiPAP) settings of 15/5 cm H2O with 35% oxygen at night
time and during daytime as needed. Arterial blood gases (ABG)
one week prior to his discharge to home showed pH 7.44, PCO2
51.9 mm Hg, PO2 51.1 mm Hg and HCO3 33.7 mEq/L with anby Elsevier B.V. All rights reserved.
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During this stay, we initiated the pre-transplant evaluation as
well as started the process for obtaining VX770 (ivacaftor)
through an expanded access program sponsored by Vertex
Pharmaceuticals.
ABG at admission showed pH 7.25, PCO2 128.1 mm Hg, PO2
81 mm Hg and HCO3 56.1 mEq/L with a 98% O2 saturation
while being on 60% oxygen via BiPAP settings of 20/8 cm H2O.
CXR showed chronic bronchiectasis and fibrotic changes with
worsening infiltrates in the right middle and lower lung lobes.
Intravenous (IV) meropenem, IV tobramycin, nebulized colistin,
oseltamivir, and aggressive airway clearance were initiated. Blood
cultures were negative, where as sputum culture grew 3 strains of
PA, and methicillin-resistant Staphylococcus aureus (MRSA).
MRSA appeared to be a newly acquired infection and IV linezolid
therapy was added to the antibiotic regimen on hospital day 3.
Through the first two weeks of his stay, respiratory status
remained tenuous, and the patient was BiPAP dependent (BiPAP
settings ranged from 20 to 25 H2O for inspiratory positive airway
pressure and 8 cm H2O for expiratory positive airway pressure)
and requiring 55%–70% supplemental oxygen. Patient was started
on VX770 (ivacaftor) on day 15 of his hospital stay. Spirometry at
that time showed forced vital capacity (FVC) 1.75 L (38%
predicted) and FEV1 0.88 L (24% predicted). His body mass
index was 36.36 (weight 102.1 kg and height 1.67 m). Within a
few days, he noticed significant subjective improvement. He
described this as “if a battery was turned on” and felt as if he was
20 years old again. Over the course of the remaining hospitali-
zation he had slowly improving respiratory status and ABGs (see
Table 1). He required less time on BiPAP and was eventually
weaned down to 5 L/min oxygen by nasal cannula and discharged
to home 17 days after starting ivacaftor. Spirometry at that time
showed FVC 2.15 L (45% predicted) and FEV1 1.22 L (32%
predicted), showing absolute FEV1 increase of 0.34 L or 8%. No
short term side effects from administration of ivacaftor were noted,
except that his blood glucose trended to low-normal, requiring less
insulin, which is a known effect of ivacaftor therapy. At 7 month
follow up visit from starting ivacaftor, he is no longer using
supplemental oxygen at rest. Spirometry showed FVC 2.30 L
(48% predicted) and FEV1 1.38 L (36% predicted), showing
absolute FEV1 increase of 0.5 L or 12% since starting ivacaftor.
His body mass index is 39.46 (weight 111.1 kg and height
1.67 m).
In addition, the patient has neither required admission to the
hospital nor outpatient therapy for pulmonary exacerbation.Table 1
Arterial blood gases (ABGs).
ABGs Ivacaftor started on day 15
Day 1 4 9 15 24 32 188
pH 7.25 7.36 7.37 7.36 7.43 7.46 7.4
pCO2 128.1 104.7 95.2 76.8 69 54.1 42
pO2 81 117.5 94.5 118.7 95.1 85.5 54
Bicarbonate 56.1 57.8 53.7 42.6 45.2 37.3 28
O2 saturation 92.0% 97.8% 96.5% 98.0% 97.3% 96.8% 89%
Supplemental O2 60% 65.0% 55.0% 55.0% 40.0% 40.0% 21%3. Discussion
The landmark studies of ivacaftor in CF patients with
G551D mutations and mild to moderate lung disease showed
that treatment resulted in significant improvement in their lung
function [1–3]. Patients also had improved weight gain and
lower sweat chloride levels. Furthermore, in these trials with
relatively short follow up, it was shown to be an overall safe
therapy with minimal side effects [1–3]. While these studies
only included patients with mild to moderate lung disease, very
little is known about the outcome in patients with severe lung
disease. While hospitalized, this patient improved significantly
only after the administration of ivacaftor suggesting a role in
recovery from pulmonary exacerbations. At his 7 month
outpatient follow up he has continued to improve, is now off
supplemental oxygen at rest, with normal PCO2 and has not had
any additional pulmonary exacerbations. While his absolute
increase in % predicted FEV1 from the time of starting
ivacaftor through month 7 was 12%, his relative increase was
56%. During this period, he has continued to receive his usual
CF therapies, with only new medication being doxycycline. His
repeat sputum cultures showed chronic MRSA infection. At
this stage, our patient has decided to forego lung transplant
evaluation because of his improvements of his lung function
and well being. While ivacaftor may be the most important
factor for such improvement, it is likely that the combined
impact of multiple interventions that were undertaken during
this period (more intense therapies, including use of monthly
nebulized antibiotics aztreonam alternating with tobramycin,
use of chronic doxycycline as well as probably better adherence
to all of these therapies), accounted for this favorable outcome.
Nevertheless, this case highlights the potential for ivacaftor to
be integral in improving the outlook of severe lung disease due
to CF and to delay the need for lung transplantation for some of
these patients. Long-term monitoring of patients on ivacaftor is
needed for further assessment of safety and efficacy, but the
recent results are promising.
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